

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: AP1/18 - Antithrombotic Agents

Dead line: 16.03.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U_{AV} = expanded uncertainty of the assigned value ($k = 2$)	

Test	[unit]	Comparability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U_{AV}	D _{max}	LL	UL	N _{eva}

Set of samples 1

(108) Apixaban	[µg/L]											20	20	19	95%
Sample A1		200	17	8,5	20	CVP	200	9,3	25%	150	250	20	19	95%	
(38) IL		216	11	5,0	5	0						5			
(193) HYPHEN BioMed		195	17	8,7	10	0						10			
Other					5	0						5			
Sample B1		416	27	6,5	20	CVP	416	15	25%	312	520	20	20	100%	
(38) IL		435	9,1	2,1	5	0						5			
(193) HYPHEN BioMed		405	19	4,8	10	0						10			
Other					5	0						5			

Set of samples 2

(109) Dabigatran	[µg/L]											26	26	26	100%
Sample A2		101	12	11	26	CVP	101	5,5	25%	75,7	127	26	26	100%	
(38) IL		102	8,8	8,6	5	0						5			
(193) HYPHEN BioMed		105	6,8	6,5	16	0						16			
Other					5	0						5			
Sample B2		303	35	11	26	CVP	303	17	25%	227	379	26	26	100%	
(38) IL		335	43	13	5	0						5			
(193) HYPHEN BioMed		310	19	6,0	16	0						16			
Other					5	0						5			

Set of samples 3

(110) Rivaroxaban	[µg/L]											30	30	28	93%
Sample A3		94,9	11	12	30	CVP	94,9	5,0	25%	71,1	119	30	28	93%	
(38) IL		90,6	8,2	9,0	7	0						7			
(193) HYPHEN BioMed		99,3	9,7	9,7	17	0						17			
Other					6	0						6			
Sample B3		299	25	8,3	30	CVP	299	11	25%	224	374	30	30	100%	
(38) IL		275	20	7,3	7	0						7			
(193) HYPHEN BioMed		307	12	4,0	17	0						17			
Other					6	0						6			

st_kn_p

End of report

Printed: 22.03.2018